Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients

被引:53
作者
Chen, Qingyong [1 ]
Fei, Jun [1 ]
Wu, Lijun [1 ]
Jiang, Zhongyong [1 ]
Wu, Yuquan [1 ]
Zheng, Yun [1 ]
Lu, Guohua [2 ]
机构
[1] 117th Hosp PLA, Dept Resp Dis, Hangzhou 310013, Zhejiang, Peoples R China
[2] Zhejiang Univ, Dept Resp Dis, Affiliated Hosp 1, Coll Med, Hangzhou 310004, Zhejiang, Peoples R China
关键词
cathepsin B; cathepsin L; cysteine C; urokinase plasminogen activator; urokinase plasminogen activator receptor; lung cancer; progonosis; sera; INHIBITORS STEFIN-A; PROGNOSTIC-SIGNIFICANCE; PULMONARY ADENOCARCINOMAS; CLINICAL-SIGNIFICANCE; CYSTEINE PROTEINASES; COLORECTAL-CANCER; EXPRESSION; METASTASIS; PROTEASES; PROGRESSION;
D O I
10.3892/ol.2011.302
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study aimed to determine the levels of cathepsin B (cath B), cathepsin L (cath L), cystatin C, urokinase plasminogen activator (u-PA) and urokinase plasminogen activator receptor (u-PAR) in the sera of patients with lung cancer compared to healthy controls using ELISA. Concomitantly, the relationship between the components and clinicopathological prognosis was analyzed. The study included 30 healthy volunteers and 105 lung cancer patients. Blood samples were collected and cath B, cath L, cystatin C, u-PA and u-PAR measurements were made using ELISA. Results showed that the levels of cath B, cath L, cystatin C, u-PA and u-PAR were significantly higher in the patient group compared to the healthy controls. The significance was marked for cath B and mild for u-PAR in correlation with lymph node metastasis. There was no significance for other parameters. Notably, patients with a combination of high cystatin C and high cath B levels had significantly lower survival probability as compared to those with cystatin C(+)/cath B(-) or with cystatin C(-)/cath B(-), Similarly, patients with a combination of high u-PA and u-PAR experienced significantly shorter survival., Furthermore, the univariate analysis revealed that cath B, u-PAR, lymph node metastases, stage and grade were related to survival. However, findings of the multivariate Cox analysis indicated that the sera levels of cath B, u-PAR and lymph node metastases may serve as independent prognostic variables in patients with lung cancer.
引用
收藏
页码:693 / 699
页数:7
相关论文
共 50 条
  • [21] Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
    Zhu, Ran
    Liu, Ting-Wei
    Liu, Fan
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [22] Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer
    Montuori, Nunzia
    Pesapane, Ada
    Rossi, Francesca W.
    Giudice, Valentina
    De Paulis, Amato
    Selleri, Carmine
    Ragno, Pia
    TRANSLATIONAL MEDICINE AT UNISA, 2016, 15 : 15 - 21
  • [23] Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients
    Pappot, H
    HoyerHansen, G
    Ronne, E
    Hansen, HH
    Brunner, N
    Dano, K
    GrondahlHansen, J
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (06) : 867 - 872
  • [24] Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors
    T Jahkola
    T Toivonen
    K von Smitten
    I Virtanen
    V-M Wasenius
    C Blomqvist
    British Journal of Cancer, 1999, 80 : 167 - 174
  • [25] Role of Urokinase Plasminogen Activator Receptor in Gastric Cancer: A Potential Therapeutic Target
    Ma, Ying-Yu
    Tao, Hou-Quan
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2012, 27 (05) : 285 - 290
  • [26] Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors
    Jahkola, T
    Toivonen, T
    von Smitten, K
    Virtanen, I
    Wasenius, VM
    Blomqvist, C
    BRITISH JOURNAL OF CANCER, 1999, 80 (1-2) : 167 - 174
  • [27] Cathepsin B/cystatin C complex levels in sera from patients with lung and colorectal cancer
    Zore, I
    Krasovec, M
    Cimerman, N
    Kuhelj, R
    Werle, B
    Nielsen, HJ
    Brünner, N
    Kos, J
    BIOLOGICAL CHEMISTRY, 2001, 382 (05) : 805 - 810
  • [28] The urokinase plasminogen activator system in breast cancer invasion and metastasis
    Tang, Linlin
    Han, Xiuzhen
    BIOMEDICINE & PHARMACOTHERAPY, 2013, 67 (02) : 179 - 182
  • [29] Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer
    Duffy, MJ
    Duggan, C
    Maguire, T
    Mulcahy, K
    Elvin, P
    McDermott, E
    Fennelly, JJ
    OHiggins, N
    ENZYME & PROTEIN, 1996, 49 (1-3) : 85 - 93
  • [30] Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients
    McCabe, NP
    Angwafo, FF
    Zaher, A
    Selman, SH
    Kouinche, A
    Jankun, J
    ONCOLOGY REPORTS, 2000, 7 (04) : 879 - 882